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Gene therapy is one potential novel
therapeutic avenue for the treatment
of inherited monogenic disorders.
Diseases of the blood are frequent
targets for gene therapy because it is
relatively easy to harvest haemato-
poietic stem cells (HSCs) from the
bone marrow, genetically modify the
cells ex vivo, and then re-administer
the corrected cells back into the
patient via intra-venous injection. In
this Closeup, Milsom and Williams
discuss the work of Roselli et al, who
describe the pre-clinical evaluation of
the treatment for b-thalassemia in
erythroid cells via the genetic
correction of patient HSCs using a
lentiviral vector.
Efforts at developing viral vectors and
gene transfer methods for molecular
therapeutic purposes continue to show
steady progress. Challenges to the ﬁeld
continue to stimulate innovation and
translational studies are key to moving
the technology forward. In this issue,
Roselli et al describe an extensive pre-
clinical assessment of a lentiviral-
mediated gene therapy approach for the
treatment of b-thalassemia (Roselli et al,
2010). The HIV1-based vector that they
describe contains elements of the b-
globinpromoterandlocuscontrolregion,
which drive the expression of an exo-
genous b-globin gene. Thus, even though
their methodology involves the ex vivo
transduction of long-lived CD34
þ hae-
matopoietic stem and progenitor cells,
the vector payload will only be tran-
scribed in the erythroid progeny of these
cells. In order to prepare for an initial
clinical trial utilizing this vector, the
authors have performed a range of in
vitro assays to evaluate the efﬁcacy and
safety of their approach using primary
CD34
þ bone marrow cells collected from
a large cohort of b-thalassemia patients
and normal donors. The content of their
manuscript can be summarized as three
key messages. Firstly, they demonstrate
that the ex vivo manipulations which are
required for the successful transduction
of haematopoietic stem cells (HSCs) with
a lentiviral vector do not adversely
impact the functional capacity of patient
CD34
þ cells, nor their global gene
expression proﬁle. Secondly, they pre-
sent data which show that at low copy
number, the lentiviral vector they are
utilizing is able to correct the deﬁciency
of adult globin expression characteristic
of b-thalassemia and restore erythropoi-
esis in the in vitro-differentiated progeny
of transduced patient CD34
þ cells.
Finally, they analyse the pattern of
lentiviral integration sites in transduced
patient CD34
þ cells and conclude that the
vector they are utilizing has preferences
for genomic integration sites similar to
those described for other lentiviral vec-
tors, with no bias towards integration in
the proximity of proto-oncogenes. Taken
together, these data suggest this vector is
safe and effective and support further
clinical development. The work repre-
sentsthekindoftranslationalstudiesthat
are required to move human investiga-
tions forward but are often very difﬁcult
to fund and publish.
What many consider the ﬁrst success-
ful trial involving the use of recombinant
retroviral vectors to correct an inherited
monogenic disorder in bone marrow-
derived HSCs was reported 10 years ago
by the group of Alain Fischer in Paris
(Cavazzana-Calvo et al, 2000). This
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study from Adrian Thrasher’s group in
London (Gaspar etal, 2004), involved the
use of a gammaretroviral vector to
deliver a complementary DNA (cDNA)
encoding the common gamma chain of
the interleukin-2 (IL-2) receptor into
CD34
þ cells isolated from patients suffer-
ing from X-linked severe combined
immunodeﬁciency (SCID-X1). These
trials undeniably demonstrated the ther-
apeutic efﬁcacy of this approach. They
were however, afterwards noted for the
subsequent iatrogenic leukaemias that
occurred as a result of retroviral vector-
mediated insertional mutagenesis
(Hacein-Bey-Abina et al, 2008; Howe
et al, 2008). Another set of gene therapy
trials using a similar vector backbone in
SCID due to adenosine deaminase deﬁ-
ciency has reported no serious adverse
events in 20 patients, some now 10 years
post-treatment. In neither disease, were
serious adverse events predicted during
the pre-clinical evaluation of gene trans-
fer. For the past 7 years, the scientists in
the gene therapy ﬁeld have strived to
develop new pre-clinical model systems
in order to evaluate and then minimize
the risk of insertional mutagenesis while
maintaining therapeutic efﬁcacy.
There is a phase one lentiviral-
mediated gene therapy trial for b-thalas-
semia directed by Philippe Leboulch
currently underway in Paris using a
similar vector conﬁguration to the one
described by Roselli et al (discussed in
Kaiser, 2009). While that work is clearly
at a more advanced stage, we believe that
there are several compelling reasons for
why it is important to publish extensive
pre-clinical studies such as Roselli et al.
Some of these are outlined below.
Detailed pre-clinical studies act as a
template which others may follow to
devise a protocol for additional clinical
trials. Developing appropriate protocols
and reagents for clinical studies is an
extremely costly and time-consuming
exercise. Therefore the publication of
successful methodologies is of particular
interest to those in the ﬁeld with aspira-
tions to translate their basic studies into
the clinic.
For a number of orphan diseases that
are, in particular, the target of gene
transfer protocols, it is difﬁcult to obtain
material from a large cohort of patients
with which to perform efﬁcacy and safety
studies. It is therefore imperative that the
groups who have access to these
resources are able to disseminate their
ﬁndings to others.
The data presented in this manuscript
can act as a yardstick against which to
gauge the effectiveness of future techni-
calmodiﬁcations.Sincethisstudyreports
detailed experimental ﬁndings such as
the degree of correction per vector copy
number; the results of this approach
across a range of b-thalassemia subtypes;
and gives an extensive integration site
proﬁle, it will be imperative for others to
directly compare their ﬁndings against
those within this publication.
Publications such as this can contri-
bute to more effective and efﬁcient
regulation of gene therapy trials. From
the point of view of the various regula-
tory bodies, well-executed pre-clinical
studies can act as a guide for recommen-
dations to other investigators developing
trials in the same disease. From the point
of view of the researcher, the studies can
act as a citable example of why their
studies have been designed in a speciﬁc
manner.
Where similar clinical trials have been
performed in parallel by different groups
withslightly differingmethodologies,itis
important to have ready access to a
wealth of pre-clinical data in any attempt
to explain differing outcomes. For
instance, in the ﬁrst successful clinical
gene therapy trial of SCID-X1, 4 out of
10 patients treated on the protocol in
Paris went on to develop T cell leukaemia
(Hacein-Bey-Abina et al, 2008). At the
sametime,inasimilarparalleltrialrunin
London (Gaspar et al, 2004), there had
been no reported incidences of adverse
events in the 10 patients treated there,
although one patient in the London trial
subsequently developed iatrogenic T cell
acute lymphoblastic leukaemia (Howe
et al, 2008). Thus during the initial time
period after the report ofleukaemia in the
trial in Paris there appeared to be a
difference in the clinical outcomes
between the two trials. A great deal of
effort was focused in an attempt to
investigate whether minor differences
in methodology such as different vector
envelope pseudotypes and culture con-
ditions could explain the lack of leukae-
mia in the London trial. Since such
variables may only have been directly
compared in pre-clinical studies, it is
possible that the retrospective analysis of
published pre-clinical data could be
informative about differential outcomes
by eliminating or highlighting speciﬁc
lines of investigation for follow-up. In
relation to this, and of direct relevance to
the current study, a non-malignant clonal
imbalance associated with a vector-
mediated insertional event has been
described in the ongoing pilot trial for
lentiviral-mediated gene therapy of b-
thalassemia (as discussed in Kaiser,
2009). The extensive insertion site ana-
lysis performed in the current study may
contribute towards the follow up analysis
and subsequent interpretation of this
event.
Last and perhaps most importantly,
retrospective analysis of pre-clinical data
and analysis of how well these data
predicted clinical trial outcome, will
facilitate the future reﬁnement of such
studies. The gene therapy ﬁeld is parti-
cularly lacking in validated assays that
one can employ to anticipate whether a
speciﬁc methodology will be effective
and/or safe (Figure 1). For example, a
number of surrogate assays have been
developed to evaluate the risk of inser-
tional mutagenesis in human HSCs
following transplant. Although these
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analysis of the probability of inducing
insertional mutagenesis in vivo in mice, it
is extremely difﬁcult to extrapolate what
these assays mean in terms of actual risk
of malignant transformation in patients.
We have recently undertaken an exten-
sive pre-clinical assessment of vector
toxicity in haematopoietic stem and
progenitor cells using a murine trans-
plant model and comparative insertion
site identiﬁcation after in vivo engraft-
ment of cells, in preparation for a second
generation clinical trial for the gene
therapy of SCID-X1 (http://clinicaltrials.
gov/ct2/show/NCT01129544). Given
that the vector conﬁguration which
promoted leukaemia in the London and
Paris clinical trials would not be pre-
dicted to elicit malignant transformation
in the assay (and indeed did not lead to
leukaemia in this new set of experi-
ments), we are unsure of how informa-
tivethedatafromthisexperimentwillbe.
Such experiments are costly, have taken
more than one year to complete, and yet
there is a real possibility that we have
gained no further insight into potential
human toxicity in the current trial.
With this in mind, we suggest that it is
of the utmost importance for the ﬁeld
to develop and validate robust assays
in human cells for the pre-clinical
assessment of human gene therapy pro-
tocols.
Considering the inherent difﬁculties
accompanying human research (low
relative number of samples, high biolo-
gical variability, difﬁculty in performing
timely follow-up experiments to address
new ﬁndings and small numbers of
repeats), studies like those reported in
this issue of EMBO Molecular Medicine
by Roselli et al are extremely important
for moving the ﬁeld forward.
The authors declare that they have no
conﬂict of interest.
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Figure 1. Current approaches for pre-clinical modeling of gene therapy strategies using established technologies.
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